ArticleOncoimmunology2013
Prostate cancer vaccines: Update on clinical development.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer.Cancer immunology, immunotherapy : CII · 2018Trial
- Structure-based identification of bioactive phytochemicals targeting kallikrein-related peptidase 2 for prostate cancer therapy.Frontiers in chemistry · 2025Article
- Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer.Life (Basel, Switzerland) · 2023Review
- Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number.Biology direct · 2022Review
- Review
- Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology.Central European journal of urology · 2021Review
- Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers.Nanomaterials (Basel, Switzerland) · 2020Review
- Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.Journal of immunology research · 2018Review
- Prostate Cancer Prevention: Concepts and Clinical Trials.Current urology reports · 2016Review
- Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.Expert opinion on biological therapy · 2014Review
- Therapeutic vaccines for cancer: an overview of clinical trials.Nature reviews. Clinical oncology · 2014Review
- KLK-targeted Therapies for Prostate Cancer.EJIFCC · 2014Article
- Applying biodegradable particles to enhance cancer vaccine efficacy.Immunologic research · 2014Review
- Trial Watch: DNA vaccines for cancer therapy.Oncoimmunology · 2014Review
- Immunotherapy and gene therapy in prostate cancer treatment.Journal of medicine and lifeArticle
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Prostate cancer is a common malignancy among elderly men and is essentially incurable once it becomes metastatic. Results from clinical trials testing a panel of specific vaccines in patients with castration-resistant prostate cancer (CRPC) suggest that alternative therapies may one day substitute or support the current gold standard (docetaxel plus prednisone). Here, we summarize the results of germane clinical trials completed during the last 12 y and provide updates on some currently ongoing studies. As it stands, prostate cancer vaccines appear to be safe and capable of generating prostate-specific T lymphocyte responses with potential antitumor activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.